Pernix Therapeutics (PTX) Reports Q3 Loss of $2.99/Share

Pernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($2.99), versus ($1.76) reported last year. Revenue for the quarter came in at $41.5 million, versus $48.6 million reported last year.

For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79